Christian Otte
Christian Otte is an expert in Psychiatry at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Christian Otte in the top 1% of experts worldwide for Depressive Disorder and depressive disorder, major. Christian Otte has authored 315 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 3 of them ongoing. SLR score: 1,207 (community average: 125). How the SLR is computed.
LeadR Profile
Psychiatry
Subspecialties: Endocrinology - Neurology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 315
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Immunometabolic alterations in post-traumatic stress disorder. PMID 42829158 — cells, genes, monocytes, stress disorders, post-traumatic, serum, oxidoreductases, killer cells, natural, stress, physiological, stress disorders, traumatic | Brain Behav Immun | 2026 | 0 |
| Mineralocorticoid receptor stimulation effects on stress-induced cortisol and alpha-amylase in female patients with borderline personality disorder and healthy controls: A randomized placebo-controlled experimental study. PMID 42800510 — alpha-amylases, feedback, personality disorders, borderline personality disorder, personality, amylases, stress, physiological, receptors, mineralocorticoid, hydrocortisone, mineralocorticoids, fludrocortisone | J Affect Disord | 2026 | 0 |
| A European platform trial for major depressive disorder. PMID 42742617 — depressive disorder, depressive disorder, major | World Psychiatry Top journal | 2026 | 0 |
| The Longevity of Mental Health Apps: A Survival Analysis of the Largest Mental Health App Database. PMID 42711750 — longevity, survival analysis, mental health, forests, psychiatry | Am J Psychiatry | 2026 | 0 |
| Analysis of soluble Triggering Receptor Expressed on Myeloid Cells-1 and -2 and Fractalkine in depression and childhood adversity: an exploratory study. PMID 42678888 — cytokines, depression, cells, stress, physiological, chemokine cx3cl1, signs and symptoms, myeloid cells, research, hydrocortisone, wounds and injuries, neurology, triggering receptor expressed on myeloid cells-1, mental health, psychiatry | Neuropsychobiology | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder NCT07775300 — depression, safety, mood disorders, signs and symptoms, depressive disorder, therapeutics, depressive disorder, major | Phase 3 | Recruiting | 2026 |
| The RAPID Elapse study Can the drug bupropion improve fatigue symptoms in patients with long COVID 2025-524443-12-00 — bupropion, pharmaceutical preparations, signs and symptoms, covid-19, fatigue, therapeutics, post-acute covid-19 syndrome | Phase 2 | Not yet recruiting | 2026 |
| Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment resistant depression a randomized controlled trial (DARE Trial) 2024-517963-21-00 — depression, antidepressive agents, dehydroepiandrosterone, therapeutics, depressive disorder, treatment-resistant | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map